Gallus Biopharmaceuticals, LLC and Roslin Cells Announce an Exclusive Partnership to Supply Cell Therapies for Clients
Gallus is an entrepreneurial, innovative, world-class CMO, operating a commercially licensed manufacturing site in St. Louis, MO. With more than 25 years of experience in process development and a decade of commercial manufacturing, the company’s facilities are designed to support the development of early-phase processes through scale-up and full clinical and commercial production. “Our intent is to leverage Gallus’ extensive development and commercial manufacturing experience with Roslin Cells’ pioneering cell therapy experience so that we can better serve clients who require regionally-based supply of cell therapy products for patients. This is just one of many examples where Gallus empowers its customers to improve patients’ lives,” said Gallus’ President and CEO Mark Bamforth.
Roslin Cells, headquartered in Edinburgh, Scotland, was established as an independent non-profit organization by the Roslin Institute in 2006 and has been a pioneer in providing ethically sourced, clinical grade pluripotent human cells manufactured to the highest quality available according to Good Manufacturing Practice (GMP) standards. The Company now occupies a seven clean room GMP Cellular Therapy Facility within the Scottish Centre for Regenerative Medicine designed solely for the manufacture of cellular therapy products. Its state of the art facilities and expert team of staff can assist both academic and commercial organizations to translate fundamental research into GMP compliant processes which can be used in the production of cell therapies. Roslin Cells’ CEO, Aidan Courtney said, “This partnership will allow Roslin Cells to bring its expertise in cell therapy to assist Gallus’ customers to develop their products regionally. Gallus has a strong track record in developing and delivering its customers’ products and we very much look forward to working with them and their customers to accelerate the delivery of these ground-breaking therapies.”
About Gallus BioPharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Mo., was established in 2010 and acquired a world-class commercial biopharmaceutical manufacturing facility and workforce from Johnson & Johnson’s Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services, visit http://www.gallusbiopharma.com, email info(at)gallusbiopharma(dot)com or call directly at (314) 426-5000.
About Roslin Cells
Roslin Cells Ltd is headquartered in Edinburgh, Scotland. It was established as an independent non-profit company by Roslin Institute in 2006 to assist academic and commercial research organizations to transform fundamental research into new cell therapies. It is currently licensed by The Human Fertilisation and Embryology Authority and the Human Tissue Authority and is currently preparing to receive a GMP Manufacturer’s license inspection from the Medicines and Healthcare Products Regulatory Agency (MHRA). With the assistance of its primary stakeholders, the Roslin Foundation, the University of Edinburgh, the Scottish National Blood Transfusion Service and Scottish Enterprise Roslin Cells is able to provide a strong partner for the development of cellular therapies. For more information please see http://www.roslincells.com, email info(at)roslincells(dot)com, or telephone +44 (0) 131 651 9610.